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Metabolic stress causes activation of the cJun NH2-terminal kinase
(JNK) signal transduction pathway. It is established that one con-
sequence of JNK activation is the development of insulin resistance
and hepatic steatosis through inhibition of the transcription factor
PPARα. Indeed, JNK1/2 deficiency in hepatocytes protects against
the development of steatosis, suggesting that JNK inhibition repre-
sents a possible treatment for this disease. However, the long-term
consequences of JNK inhibition have not been evaluated. Here we
demonstrate that hepatic JNK controls bile acid production. We found
that hepatic JNK deficiency alters cholesterol metabolism and bile acid
synthesis, conjugation, and transport, resulting in cholestasis, increased
cholangiocyte proliferation, and intrahepatic cholangiocarcinoma. Gene
ablation studies confirmed that PPARαmediated these effects of JNK in
hepatocytes. This analysis highlights potential consequences of long-
term use of JNK inhibitors for the treatment of metabolic syndrome.
JNK | PPARa | bile acid | cholangiocarcinoma
Liver cancer is the fifthmost common cancer and the second leadingcause of cancer deaths worldwide (1, 2). Cholangiocarcinoma the
second most common liver cancer, is a malignancy of bile duct epi-
thelia with a clinically silent development and an increasing global
incidence (3). Due to the absence of early markers for its diagnosis,
most cholangiocarcinoma patients are identified at an advanced stage
and die of metastasis (4).
Hepatic cJun NH2-terminal kinase (JNK) has been identified
as a signal transduction pathway that is critically required for
obesity-induced insulin resistance and hepatic steatosis (5, 6).
Indeed, mice with hepatocyte-specific JNK deficiency are re-
sistant to high-fat diet–induced insulin resistance and steatosis
(7); therefore, this signaling pathway represents a potential tar-
get for therapeutic intervention. Biochemical studies demon-
strate that JNK suppresses Peroxisome Proliferator-activated
Receptor α (PPARα) activation in hepatocytes, affecting lipid
metabolism and steatosis through the hepatokine FGF21
(encoded by a PPARα target gene) (7, 8).
The transcription factor PPARα plays a pivotal role in in-
tracellular free fatty acid and triglyceride metabolism by regu-
lating genes involved in fatty acid transport and degradation in
mitochondria and peroxisomes (9–11). PPARα is expressed
primarily in liver, heart, and muscle and is a major regulator of
fatty acid transport, catabolism, and energy homeostasis (12).
PPARα activation in the liver is increased in metabolic diseases
and obesity (12), and PPARα agonists appear to be therapeuti-
cally beneficial for the treatment of metabolic syndrome. Indeed,
PPARα activity protects against steatosis in the mouse (13) and
suppresses hepatic inflammation (14). However, long-term
studies in rodents showed an association of PPARα agonists
with hepatic carcinogenesis (15). These findings conflict with
the growth inhibitory effects reported for PPARα agonists in
cancer cell lines, including liver cancer cell lines (16–18). PPARα
may therefore cause context-specific actions on liver cancer
development.
The activation of PPARα modifies bile acid (BA) synthesis,
conjugation, and transport (19). This change in BA metabolism
can protect against steatosis, but may also promote liver cancer.
An example is represented by fibroblast growth factor 15/19
(FGF15/19) that is expressed in the liver during the development of
hepatocellular carcinoma and intrahepatic cholangiocarcinoma (20,
21). Notably, FGF15/19 improves glycemic responses and reduces
hepatic steatosis, but also promotes liver cancer (22). These func-
tions of BAs prompted us to examine whether long-term blockade
of JNK signaling in hepatocytes, and the resulting activation of
PPARα, could alter BA homeostasis and promote liver disease.
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Hepatic JNK Deficiency Alters Bile Acid Homeostasis. We have pre-
viously shown that hepatic JNK deficiency results in the activa-
tion of the transcription factor PPARα and causes protection
against diet-induced insulin resistance and hepatic steatosis (7).
The activation of PPARα may cause altered BA metabolism
(19). We therefore examined BA in hepatic JNK1 plus JNK2-
deficient mice (LDKO) and control mice (LWT) at 6 mo of age.
We found that the total BA concentration in the blood of LDKO
mice was significantly increased compared with LWT mice
(Fig. 1A). The increase in circulating BA concentration is con-
sistent with the possibility that LDKO mice exhibit cholestasis.
Analysis of bile collected from the gall bladder of LDKO and
LWT mice revealed significantly increased amounts of BA rela-
tive to the amount of cholesterol and phosphatidylcholine (PC)
(Fig. 1B). Hepatic expression of genes related to hepatic PC
synthesis (Scd2, Chpt1, and Chkb) or hepatocyte-mediated
transport of PC (Abcb4 and Atp8b1) and BA (Abc11 and
Slc10a1) was markedly increased in LDKO mice (SI Appendix,
Fig. S1 A and B). Similarly, increased expression of genes related
to cholesterol synthesis (Hmgcs1, Hmgcr) and BA synthesis
(Baat, Cyp8b1 and Cyp27a) was detected in LDKO mice (Fig. 1C).
These data are consistent with altered biosynthesis and secretion
of both cholesterol and BA through PPARα activation.
Hepatic JNK Deficiency Causes Cholestasis and Liver Damage. It is
established that cholangitis is a major risk factor for the devel-
opment of cholangiocarcinoma (23). We therefore examined the
liver of mature adult LDKO and LWT mice. No evidence of he-
patic disease was found in LWT mice. Similarly, analysis of he-
patic sections prepared from young adult LDKO mice (age 4 mo)
did not indicate the presence of liver pathology (SI Appendix,
Fig. S1C). However, at age 10 mo, 82% of LDKO mice displayed
multifocal bile duct hyperplasia together with fibrosis and in-
flammatory cell infiltrates (Fig. 1D). Cholangiocytes stained
positively with PCNA (proliferating cell nuclear antigen), a
marker for proliferation (Fig. 1D). These changes were associ-
ated with increased expression of myeloid genes (Cd68 and Lyz)
and inflammatory cytokines (Ifng, Tnf, Il10, and Il12a) in the
liver (Fig. 1E) and increased liver damage, as monitored by the
high levels of liver enzymes (ALT, AST, and γ-GT) in the blood
of LDKO mice (Fig. 1F). The remaining LDKO mice exhibited
intrahepatic cholangiocarcinoma (6%) or appeared to be healthy
(12%). At age 14 mo, 95% of LDKO mice displayed intrahepatic
cholangiocarcinoma (Fig. 2A) associated with fibrosis (Fig. 2B)
and a large increase in liver mass together with significant in-
creases in serum levels of ALT and AST (Fig. 2C). The
remaining LDKO mice (6%) exhibited cystic livers with bile duct
hyperplasia. Histological analysis indicated increased staining for
glutamine synthetase (GS) in liver tumor lesions, together with
neoplastic nodules with positive staining of the ductular markers
CK19 and Sox9 (Fig. 2D). Together, these data confirm that the
majority of mature mice with compound deficiency of JNK1 and
JNK2 progressively develop intrahepatic cholangiocarcinoma.
The development of bile duct hyperplasia and intrahepatic
cholangiocarcinoma in LDKO mice was associated with increased
hepatic expression of Cytokeratin 19 (Krt19), a cholangiocyte-
specific epithelial marker, together with the G protein-coupled
BA receptor 1 (Gpbar1) and the apical sodium-dependent BA
transporter (Slc10a2) that are expressed in cholangiocytes (24,
25) (Fig. 3A). The Notch receptor ligand Jagged-1 promotes the
formation of intrahepatic bile ducts (26) and was overexpressed
in the liver of LDKO mice (Fig. 3A). Moreover, bone morpho-
genetic protein 4 (Bmp4) mediates cholestasis-induced fibrosis
(27) and cooperates with FGF to promote the development of
cholangiocytes from hepatoblasts (28); expression of hepatic
Bmp4 was increased in LDKO mice compared with LWT mice
(Fig. 3A). Hepatoblasts can differentiate to cholangiocytes
through activation of the ERK pathway (29), and BA can in-
crease proliferation by ERK activation through the FXR/FGF15/
FGFR4 pathway (30). We evaluated this pathway in mice, before
cancer has developed. In concordance with elevated BA pro-
duction, we found increased Farnesoid X receptor (FXR) ac-
tivity, as monitored by high levels of FXR target gene (Shp and
Fgfr4) expression, in LDKO mice (Fig. 3B). Moreover, while
control mice did not express Fgf15, we could detect Fgf15 mRNA
(messenger RNA) in LDKO livers (Fig. 3B). Moreover, histo-
logical analysis indicated increased staining of phospho-ERK in
cholangiocytes from LDKO mice compared with LWT mice
(Fig. 3C). The increased phospho-ERK in cholangiocytes, but
not hepatocytes, was confirmed by immunoblot analysis
(Fig. 3D). Together, these changes in FXR/FGF15/FGFR4/ERK
pathway activity may contribute to cholangiocyte proliferation
and maturation from hepatoblasts, resulting in bile duct hyper-
plasia and the development of cholangiocarcinoma detected in
LDKO mice.
PPARα Deficiency Reduces Liver Cancer in JNK1/2 Deficient Liver. We
examined hepatic gene expression in chow-fed WT and LDKO
mice using RNA-seq data (7) and found evidence for activation
of PPARα and FXR transcription factors in the liver of LDKO
mice compared to LWT mice (SI Appendix, Fig. S2). To test the
role of PPARα, we ablated the Ppara gene in LDKO mice to
examine whether PPARα is required for the development of
intrahepatic cholangiocarcinoma. PPARα plus JNK1/2 liver-
deficient mice (LPPARαDKO) exhibited reduced tumor burden
and tumor incidence compared with LDKO mice (Fig. 4A). The
major changes in BA were also reversed (Fig. 4B). This is con-
sistent with reduced hepatic expression in LPPARαDKO mice of
genes involved in cholesterol and BA synthesis (Hmgcr, Baat,
Cyp8b1, and Cyp27a) and hepatocyte-mediated BA transport
(Abc11, Abc4, Abcg5, Abcg8) (Fig. 4C). Histological analyses
indicated that PPARα deficiency caused increased liver steatosis,
but reduced hallmarks of carcinogenesis (anisokaryosis, apo-
ptosis, ductogenesis, dysplasia, and mitosis) in LPPARαDKO
compared with LDKO mice (Table 1 and Fig. 4D). Moreover,
CK19 and SOX9 staining were increased in LDKO mice com-
pared with LPPARαDKO, consistent with cholangiocyte pro-
liferation. Furthermore, the prominent staining for GS by liver
tumor lesions in LDKO mice was suppressed in the liver of
LPPARαDKO mice (Fig. 4D).
Gene expression analysis demonstrated that both in-
flammation and cholangiocarcinoma markers were reduced in
LPPARαDKO mice compared with LDKO mice (Fig. 5 A and B).
This evidence suggests that PPARα deficiency protected against
the promotion of cholangiocyte proliferation in mice lacking
hepatocyte JNK1/2. To evaluate whether PPARα deficiency and
subsequent normalization of BA production blunted the FXR/
FGF15/FGFR4/ERK pathway, we evaluated FXR target gene
expression. We found that hepatic expression of Fgf15 and Shp
was reduced in LPPARαDKO mice compared with LDKO mice
(Fig. 5C). Indeed, immunoblot analysis confirmed that PPARα
deficiency suppressed the increased FGF15/21 expression de-
tected in JNK-deficient cholangiocytes (Fig. 5D). This is consis-
tent with the observation of lower levels of ERK activation,
detected by immunohistochemistry, in LPPARαDKO cholangiocytes
(Fig. 5E).
Discussion
Since increased BA can lead to inflammation, apoptosis, and
necrosis of hepatocytes (31, 32), long-term elevated BA levels in
patients are considered a risk factor for liver cancer development
(33). Indeed, serum BA might be useful for the diagnosis of
cholangiocarcinoma (34). Our findings provide an animal model


















































in which defects in BA homeostasis are linked to cholangiocarcinoma
(Fig. 6).
Previous studies have established that hepatic JNK deficiency
can suppress cholangiocyte proliferation and oncogenic trans-
formation in a p53/Kras-induced model of cholangiosarcoma
(35) and promotes cholangiocarcinoma in dethylnitrosamine and
NEMO deficiency models of liver cancer (36). The results of the
present study demonstrate that hepatic JNK deficiency is suffi-
cient for the development of cholangiocyte malignancy (Fig. 2).
PPARα is an important modulator of liver metabolism con-
trolling lipid and BA homeostasis, and its activation has been
shown to decrease fatty liver disease (19, 37, 38). We report that
JNK-mediated repression of PPARα causes changes in BA ho-
meostasis which suppress cholangiocyte proliferation. Conse-
quently, JNK deficiency stimulates cholangiocyte proliferation
and promotes the development of cholangiocarcinoma. This in-
creased proliferation is mediated by the altered BA metabolism
and the elevated hepatic expression of FXR/FGF15/FGFR4 that
Fig. 1. Hepatic JNK deficiency alters bile acid production and causes cholestasis. (A) LWT and LDKO mice (age 6 mo) were fasted overnight, and blood was
collected for measuring bile acids (mean ± SEM; n = 6–11). Student’s t test differences between LDKO and LWT are indicated (**P < 0.01). (B) The composition of
bile fluid collected from the gall bladder was examined by measurement of the ratio of BAs to cholesterol (Chol) or PC and the different type of BA. TCA,
taurocholic acid; TMCA, tauromuricholic acids. The data presented are the mean ± SEM (n = 4–5). Student’s t test differences between LDKO and LWT are
indicated (*P < 0.05; **P < 0.01). (C) LKO and LWT mice (age 6 mo) were fasted overnight prior to removal of the liver. The expression of genes related to
cholesterol synthesis (Hmgcr and Hmgcs1) and BA synthesis (Cyp7a1, Cyp7b1, Cyp27a1, Baat, Cyp27a, Cyp8b1) was measured by quantitative RT-PCR (mean ±
SEM; n = 5–6) and normalized to the amount of 18S RNA in each sample. Student’s t test differences between LDKO and LWT are indicated (*P < 0.05; **P <
0.01). (D) Representative liver sections prepared from mice (age 10 mo) stained with hematoxylin and eosin (H&E), an antibody to PCNA, and Masson Tri-
chrome (Trichrome) are presented. (Scale bar, 100 μm.) (E) The expression of genes related to inflammation was evaluated by RT-PCR. (mean ± SEM; n = 5–6)
and normalized to the amount of 18S RNA in each sample. Student’s t test differences between LDKO and LWT are indicated (*P < 0.05). (F) Liver damage
assessed from serum measurements of ALT, AST, and γ-GT. (mean ± SEM; n = 11–24). Student’s t test differences between LDKO and LWT are indicated (*P <
0.05; **P < 0.01, ***P < 0.001).








































triggers ERK activation in cholangiocytes (Fig. 6). Our results
have strong translational implications for obesity treatment.
Activation of FXR by BA triggers the secretion of FGF15/
FGF19 in humans (39), and the beneficial effects of FGF ex-
pression on the obese metabolic profile has been well charac-
terized (40). However, the clinical use of FGF has been debated
due to the potential for increasing liver tumor development
(41, 42).
Hepatic PPARα is an important mediator of this regulatory
cascade. Indeed, PPARα deficiency dramatically suppresses the
phenotypes caused by JNK deficiency. Nevertheless, the role of
PPARα in liver cancer remains unclear. While some studies have
demonstrated that PPARα activation might promote liver cancer
(43–45), others indicate that PPARα activation may be neutral
or suppress liver cancer development (46–49). This could be due
to different experimental conditions used in these studies. In our
Fig. 2. Hepatic JNK deficiency progress to cholangiocarcinoma. (A) Representative livers of LWT and LDKO mice at age 14 mo are shown. (B) Representative
sections of the liver of chow-fed LDKO mice stained with H&E and Masson Trichrome (Trichrome). (Scale bar, 100 μm.) (C) The liver mass and liver damage
measured by levels of ALT and AST (mean ± SEM; n = 11–20) are presented. Student’s t test differences between LDKO and LWT are indicated (**P < 0.01,
***P < 0.001). (D) Representative liver sections of 10-mo-old LDKO and LWT mice stained with GS, Cytokeratin 19 (CK19), and Sox9. (Scale bar, 100 μm.)
Fig. 3. ERK pathway activation accompanies the development of cholangiocarcinoma induced by hepatic JNK deficiency. (A) The expression of genes related
to cholangiocytes proliferation was evaluated by RT-PCR in 14-mo-old LWT and LDKO mice and normalized to the amount of 18S RNA in each sample (mean ±
SEM; n = 5–6). Student’s t test differences between LDKO and LWT are indicated (*P < 0.05; **P < 0.01). (B) The expression of genes related to the nuclear factor
FXR (Fxr, Fxrb, Shp, Fgfr4) and Fgf15 was measured by quantitative RT-PCR in LWT and LDKO liver from mice at age 6 mo (mean ± SEM; n = 5–6) normalized to
the amount of Actb mRNA in each sample. Student’s t tests between LDKO and LWT are indicated (*P < 0.05; **P < 0.01, ***P < 0.001). (C) Representative liver
sections of LDKO and LWT mice (age 10 mo) stained with phospho-ERK. (Scale bar, 100 μm.) (D) Comparative protein expression of ErbB2, phospho-ERK, and
JNK1 in hepatocytes and cholangiocytes in LWT and LDKO mice was evaluated by immunoblot analysis. Vinculin was used as a loading control.


















































system, the protumorigenic effect of PPARα activation is due, in
part, to an alteration in BA metabolism that drives ERK acti-
vation, suggesting that PPARα activation is a critical factor in
cholangiocarcinoma development and progression.
The role of JNK/PPARα/FGF signaling in lipid metabolism
suggests that this pathway could represent a target for the
treatment for steatosis and obesity. However, the possible con-
tribution of this pathway to carcinogenic progression represents
a serious problem for long-term treatment. Our analysis suggests
that treatment strategies using long-term JNK inhibition should
consider the potential risk of cholangiocarcinoma development
among the possible secondary effects of this treatment.
Methods
Animals. PPARα knockout mice (B6;129S4-Pparatm1Gonz/J; RRID:IMSR_JAX:008154)
and Albumin-Cre mice (B6.Cg-Speer6-ps1Tg(Alb-cre)21Mng/J; RRID:IMSR_JAX:003574)
were purchased from the Jackson Laboratory and backcrossed for 10 genera-
tions to the C57BL/6J background (Jackson Laboratory; RRID:IMSR_JAX:000664).
Mice with compound JNK1/2 deficiency in hepatocytes (LDKO) have been de-
scribed (50, 51). Genotypes were identified by PCR analysis of genomic DNA
isolated from mouse tails. All experiments were performed using male mice.
Mice were housed in a pathogen-free animal facility and kept on a 12-h light/
dark cycle at constant temperature and humidity.
All animal experiments conformed to European Union (EU) Directive 2010/
63EU and Recommendation 2007/526/EC, enforced in Spanish law under Real
Decreto 53/2013 and the Institutional Animal Care and Use Committee of the
University of Massachusetts Medical School.
Serum Analysis. Plasma transaminase activity was assessed with the ALT and
AST Reagent Kit (Biosystems Reagents) using a Benchmark Plus microplate
spectrophotometer (Bio-Rad). Plasma concentration of nonsulfated bile acids was
measured with the Bile Acid Assay Kit (Sigma-Aldrich) using a Fluoroskan
Ascent fluorescence multiwell plate reader (Thermo Labsystems).
Fig. 4. PPARα deficiency reduces liver cancer induced by hepatic JNK deficiency. (A) Representative livers, tumor burden, and incidence in 11-mo-old LWT,
LDKO, and LPPARαDKO mice (mean ± SEM; n = 14 ∼ 25). (B) The amount of bile acid in the blood was measured (mean ± SE; n = 7–11). The composition of bile
fluid collected from the gall bladder was examined. Two-way ANOVA differences between LPPARαDKO, LDKO, and LWT are indicated (*P < 0.05; **P < 0.01). (C)
The expression of genes related to cholesterol synthesis (Hmgcr and Hmgcs1), BA synthesis, and transporters (Cyp27a1, Baat, Cyp27a, Cyp8b1, Abcb11, Abcb4,
Abcg5, Abcg8) was measured by quantitative RT-PCR (mean ± SEM; n = 5–8) normalized to the amount of Actb mRNA in each sample. Two-way ANOVA
differences between LDKO and LPPARαDKO are indicated (*P < 0.05; **P < 0.01, ***P < 0.001). (D) Representative liver sections of 10-mo-old LWT, LDKO, and
LPPARαDKO mice stained with GS, Cytokeratin 19 (CK19), and Sox9. (Scale bar, 100 μm.)
Table 1. PPARα deficiency reduces carcinogenesis markers in
JNK1/2-deficient livers
LWT LDKO LPPARαDKO
Anisokaryosis − ++ +
Apoptosis − +++ +
Necrotic foci − +++ ++
Cellular hypertrophy − +++ ++
Ductogenesis − +++ +
Cystogenesis − +++ ++
Microsteatosis + + +++
Macrosteatosis − ++ +++
Lymphocytic inflammation − +++ +
Dysplasia − +++ +
Mitosis + +++ +








































Histochemistry. Histology was performed using tissue fixed in 10% formalin
for 24 h, dehydrated, and embedded in paraffin. Sections (7 μm)were cut and
stained using hematoxylin and eosin (American Master Tech Scientific).
Sections were also incubated with Bouin´s fluid overnight, counterstain with
hematoxylin (Sigma), and then stained with Masson-Trichrome stain (American
Master Tech Scientific). Immunohistochemistry was performed by staining tissue
sections with antibodies against PCNA (biotinylated from Thermofisher MS-106-B;
RRID:AB_64272), SOX9 (Abcam ab3697; RRID:AB_304012), glutamine synthetase
(Abcam ab73593; RRID:AB_2247588), cytokeratin 19 (Abcam ab15463; RRID:AB_
2281021), or phospho-p44/42 MAPK (Thr202/Tyr204) (Cell Signaling Technology
#9101). Streptavidin-conjugated horseradish peroxidase (Biogenex) and the sub-
strate 3,3′-diaminobenzidene (Vector Laboratories) were used followed by brief
counterstaining with Mayer’s hematoxylin (Sigma).
Analysis of Biliary Lipids. Bile was collected from the gall bladder following
cholecystectomy. We determined cholesterol and phospholipids using an
enzymatic assay (Wako). Total bile acids were measured using Hall’s Bile Stain
Kit (American MasterTech). Bile acid species were examined by a modifica-
tion of the method described by ref. 52 using an HPLC-MS/MS (6410 Triple
Quad LC/MS, Agilent Technologies). Chromatographic separation was
achieved with gradient elution using a Zorbax Eclipse XDB-C18 column
(150 × 4.6 mm, 5 μm) kept at 35 °C and a flow rate of 500 μL/min. Initial
mobile phase was 80:20 methanol/water, both containing 5 mM ammonium
acetate and 0.01% formic acid, pH 4.6, and it was changed to 97:3 methanol/
water over 9 min and then returned to 80:20 in 1 min. Electrospray ioniza-
tion in negative mode was used, with the following conditions: gas tem-
perature 350 °C, gas flow 8 L/min, nebulizer 10 psi, capillary voltage 2,500 V.
MS/MS acquisition was performed in multiple reaction monitoring mode
using the specific m/z transitions: [M-H]− ion to 80.2 for taurine-conjugated
bile acids and [M-H]− ion to 74 for glycine-conjugated bile acids. Free bile
acids did not generate characteristic ion fragments, as reported by others
(52), and transition from unfragmented precursor molecular ions
407.1–407.1, 391.3–391.3, and 375.3–375.3 were selected for trihydroxy-
lated, dehydroxylated, and monohydroxylated free bile acids, respectively.
Isolation of Hepatocytes and Cholangiocytes.Mice livers were perfused using a
peristaltic pump with 40 mL of Hanks Balanced Salt Solution (with 10 mM
Hepes [pH 7.4] and 1 mM EGTA; without MgCl2 and CaCl2) and then with
Fig. 5. PPARα deficiency reduces liver cholangiocarcinoma induced by hepatic JNK deficiency. (A and B) The expression of genes related to inflammation and
cholangiocarcinoma was evaluated by quantitative RT-PCR (mean ± SEM; n = 4–8) normalizing to the amount of ActbmRNA in each sample. Two-way ANOVA
differences between LDKO and LPPARαDKO are indicated (*P < 0.05; **P < 0.01, ***P < 0.001). (C) The expression of genes related to nuclear factor FXR pathway
(Fxr, Fxrb, Shp, Fgfr4, and Fgf15) was evaluated in LKO and LPPARαDKO livers by quantitative RT-PCR (mean ± SEM; n = 6–8) normalizing to the amount of Actb
mRNA in each sample. Student’s t test differences between LDKO and LPPARαDKO are indicated (*P < 0.05; **P < 0.01). (D) Representative Western blots of
ErbB2, FGF15, and FGF21 in cholangiocytes in LDKO, LPPARαDKO, and LWT mice (n = 3). Vinculin was used as a loading control. (E) Representative sections of the
liver of 10-mo-old LDKO, LPPARαDKO, and LWT mice stained with Phospho-ERK. (Scale bar, 100 μm.)


















































1 mg/mL of collagenase type I (Worthington). Hepatocytes were collected as
a cell suspension in Dulbecco’s Modified Eagle’s Medium/F12 Medium (10%
FBS, 0.2 mg/mL BSA, 5% sodium pyruvate, 10 mM Hepes [pH 7.4], 1%
L-glutamine, 1% Penicillin/Streptomycin, 0.51 mg/mL NaHCO3). Biliary trees
were collected in Williams´medium supplemented with 5 mM Hepes (pH 7.4)
and 1 mg/mL collagenase type I prior to incubation (1 h) at 37 °C to isolate
cholangiocytes. The cells were washed with PBS before protein extraction as
previously described (53).
Western Blot Analysis. Hepatocytes and cholangiocytes proteins were
extracted in lysis buffer (50 mM Tris·HCl pH 7.5, 1 mM EGTA, 1 mM EDTA pH
8.0, 50 mM sodium fluoride, 1 mM sodium β-glycerophosphate, 5 mM so-
dium pyrophosphate, 1 mM sodium orthovanadate, 0.27 M sucrose, 1%
Triton X-100, 0.1 mM PMSF, 0.1% 2-mercaptoethanol, 1 μg/mL leupeptin,
and 1 μg/mL aprotinin). Extracts were separated by SDS–PAGE and transferred to
0.2-μm pore-size nitrocellulose membranes (Bio-Rad). Blots were probed with
primary antibodies to ErbB2 (Cat# ab16901, Abcam; RRID: AB_443537), phospho-
ERK (Cat#9101, Cell Signaling Biotechnology; RRID: AB_330744), JNK1
(Cat# sc-1648, Santa Cruz Biotechnology; RRID:vAB_675868), FGF-15 (Cat#
sc-514647, Santa Cruz Biotechnology), FGF-21 (Cat# RD281108100, Bio-
Vendor Laboratory Medicine; RRID: AB_2034054), and Vinculin (Cat#V4505,
Sigma; RRID:AB_477617). All antibodies were used at 1:1,000 dilution. The
membranes were washed and incubated with an appropriate horseradish
peroxidase-conjugated secondary antibody (GE Healthcare), and immune
complexes were detected using an enhanced chemiluminescent substrate
(Clarity Western ECL substrate; Bio-Rad).
RNA-seq Analysis. Liver RNA-seq data from chow-fed LWT and LDKO (GEO
GSE55190) were examined (7). Sequencing reads were preprocessed by
means of a pipeline that used FastQC, to assess read quality, and Cutadapt to
trim sequencing reads, eliminating Illumina adaptor remains, and to discard
reads that were shorter than 30 bp. Resulting reads were mapped against
reference transcriptome GRCm38.91 and quantified using RSEM. Percent-
ages of reads participating in at least one reported alignment were around
80%. Expected expression counts calculated with RSEM were then processed
with an analysis pipeline that used the Bioconductor package Limma for
normalization (using TMM method) and differential expression testing,
taking only into account those genes expressed with at least 1 count per
million in a number of samples equal to the number of replicate samples of
the condition with less replicates. Significant expression changes between
wild type (WT) and JNK1/2 double-KO conditions, with Benjamini and
Hochberg adjusted P value < 0.05, were detected for 44 genes. Given that
the collection of differentially expressed genes was relatively small, an ad-
justed P value threshold of 0.2 was applied for further analyses. The
resulting collection of 739 genes was then used for functional enrichment
analyses with IPA (Ingenuity Pathway Analysis), to discover overrepresented
gene lists derived from Ingenuity’s proprietary knowledge-base (IPAKB).
IPAKB-derived gene lists consisted of collections of genes belonging to the
same signaling or metabolic pathway (Canonical Pathway analyses), or
regulated by the same molecule (Upstream Regulator analyses). In general,
enrichments associated to Benjamini-Hochberg adjusted P value < 0.05 are
considered significant. Importantly, IPA may issue predictions on the acti-
vation state of pathways or regulators in the form of a parameter called z
score; activation or inhibition is indicated by positive or negative values,
respectively. Other data manipulations and graphical representations
(heatmaps, bar plots, and scatter plots) were produced with statistical
package R.
Real-Time qPCR. Total RNA was isolated from liver and tumor tissue using the
RNeasy Mini Kit (Qiagen) with on-column DNase I-digestion. cDNA (com-
plementary DNA) was synthesized with the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). Taqman© assays were performed
using the probes listed in SI Appendix, Table S1 (Applied Biosystems). Se-
quences of primers used for quantitative real-time PCR (RT-PCR) are pro-
vided in SI Appendix, Table S2. Expression levels were normalized to 18S
using Taqman© assays (430449011032, Applied Biosystems) (Figs. 1 and 3A
and SI Appendix, Fig. S1) or Actb (Figs. 3B, 4, and 5) mRNA. qRT-PCR was
performed using the Fast SYBR Green system (Applied Biosystems) in a
7900HT Fast Real-Time PCR thermal cycler (Applied Biosystems). A dissocia-
tion curve program was employed after each reaction to verify purity of the
PCR products. The expression of mRNA was examined by quantitative PCR
analysis using a 7500 Fast Real-Time PCR machine.
Statistics. Differences between groups were examined for statistical signifi-
cance using two-tailed unpaired Student’s t test (with Welch’s correction
when variances were different) or ANOVA coupled to Bonferroni’s post-
test. Kaplan-Meier analysis was performed using the log-rank test. Sta-
tistical details and experimental n are specified in figure legends.
Fig. 6. Schematic illustration of JNK-regulated cholangiocarcinoma development in the liver.








































Statistical analyses were performed with the GraphPad Prism 7 software
(RRID:SCR_002798).
Material and Data Availability. Sources for materials used in this study are
described in Methods. The raw data obtained for this study are presented in
SI Appendix, Fig. 3D and Dataset S1.
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